Genentech, a member of the Roche Group, is pioneering the use of generative AI to discover and develop new therapeutics and deliver treatments to patients more efficiently.
A new collaboration between Genentech, the biotechnology pioneer, and NVIDIA aims to transform the discovery and development of new medicines by bringing together experts from each company to optimize and accelerate Genentech’s proprietary algorithms.
NVIDIA will work with Genentech to accelerate these models on NVIDIA DGX Cloud, which provides dedicated instances of AI supercomputing and software hosted by NVIDIA cloud service provider partners.
Genentech plans to use NVIDIA BioNeMo, which enables biotech companies to customize models at scale, and integrate BioNeMo cloud application programming interfaces directly into computational drug discovery workflows.
BioNeMo, now generally available as a training service, is a domain-specific platform that simplifies, accelerates and scales generative AI applications for computational drug discovery. It allows researchers to pretrain or fine-tune state-of-the-art models on DGX Cloud.